Welcome to Assurentry! New FDA compliance features available.
Skip to main content
Assurentry
Services
FDA Food Facility RegistrationDrug Establishment RegistrationMedical Device RegistrationCosmetic Registration (MoCRA)US Agent ServicesFSVP CompliancePrior Notice FilingLabeling ComplianceView All Services
US Agent
US Agent ServicesFood FacilitiesDrug EstablishmentsCosmetics (MoCRA)Medical Devices
Industries
Cosmetics & BeautyDietary SupplementsPharmaceuticalsMedical DevicesFood ImportNutraceuticalsCBD & HempAmazon SellersView All Industries
Tools
Compliance CalculatorProduct Code LookupRequirement CheckerRenewal CheckerDeadline CalculatorFEI & DUNS HelperWarning Letters BrowserImport Alert CheckerView All Tools
Resources
GuidesCase StudiesBlogCompliance PlaybooksCompare ProvidersFAQGlossaryUse CasesView All Resources
Pricing
Sign inRegister with FDA
Illustrative scenario — not a real named client

Pharmaceutical Multi-Facility Registration

An illustrative scenario showing how a pharmaceutical company can streamline FDA registration and listing across multiple global facilities from one dashboard — improving oversight and consistency and reducing duplicated overhead.

Multi-Facility
Registration + listing
One Dashboard
Centralized oversight
Renewals
Coordinated tracking

The Scenario

Consider a global pharmaceutical company specializing in generic medications, with a dozen manufacturing facilities across several countries and hundreds of products in the US market — a setup that creates significant complexity in managing FDA compliance. The walkthrough below shows how Assurentry's multi-facility workflow applies; the company and figures are illustrative.

Global Footprint

Facilities:
12 manufacturing sites
Countries:
India, Germany, Brazil, Mexico, USA, Canada
US Products:
500+ NDCs
Annual FDA Fees:
$4.2M (GDUFA)

The Challenge

A decentralized approach to FDA compliance tends to lead to inefficiencies, inconsistencies, and escalating costs. When each facility manages its own registrations with different local consultants, the result is duplicated effort and compliance gaps.

Pain Points

  • •Inconsistent registration and listing data across facilities
  • •Missed renewal deadlines causing registration lapses
  • •8 different regulatory consultants with varying quality
  • •No centralized view of compliance status
  • •GDUFA fee optimization opportunities being missed

The Solution

We implemented a comprehensive centralized compliance program that brought all facilities under unified management:

Phase 1: Assessment and Consolidation (Month 1-2)

  • Complete audit of registration status for all 12 facilities under 21 CFR Part 207 (drug establishment registration) and 21 CFR Part 207.33 (product listing requirements). Verified each facility's DUNS number, FEI number, and registration status in FDA's Unified Registration and Listing System (FURLS)
  • Inventory of 500+ NDC (National Drug Code) product listings with accuracy verification -- cross-referenced each NDC against the SPL (Structured Product Labeling) submissions on file to identify discrepancies in labeling data, active ingredients, and dosage forms
  • Gap analysis identifying 127 inconsistencies and errors including outdated labeling agents, incorrect establishment types, and missing annual product listing updates
  • Transition from 8 separate regulatory consultants across 6 countries to a single point of management through Assurentry, eliminating coordination overhead and ensuring consistent quality

Phase 2: Remediation (Month 2-4)

  • Corrected all 127 listing errors and inconsistencies through updated SPL submissions to FDA -- each SPL was reviewed for accuracy in active ingredients, dosage forms, routes of administration, and establishment roles
  • Standardized data formats across all facilities to ensure consistent FEI/DUNS linkages, establishment type designations, and registration activity codes
  • Resolved 3 lapsed registrations before FDA took action -- drug establishment registrations must be renewed annually (October 1 - December 31), and a lapsed registration can trigger FDA enforcement including Warning Letters, import alerts, and product seizure
  • Updated US Agent designations for 8 foreign facilities per 21 CFR 207.40, ensuring each foreign establishment had a properly designated US Agent with 24/7 FDA communication capability

Phase 3: Optimization (Month 4-6)

  • Implemented centralized compliance dashboard with real-time registration status tracking across all 12 facilities and 500+ products
  • Established automated renewal reminders with 90/60/30-day advance notifications for the October-December annual registration window
  • Optimized GDUFA (Generic Drug User Fee Act) fee payments through proper facility categorization -- correctly identified 2 facilities as API-only sites qualifying for lower GDUFA self-identified facility fees ($229,070 vs. the finished dosage form rate), saving $45,000 annually
  • Created standardized SOPs for global compliance team covering registration maintenance, product listing updates, SPL submission procedures, and US Agent communication protocols

The Results

Renewals on Track

Every facility's registration and renewal window is tracked centrally, so deadlines are surfaced before they lapse instead of being missed across scattered consultants.

Lower Overhead

Consolidating from many local consultants to one workflow removes duplicated effort and supports proper GDUFA fee categorization across sites.

Unified Oversight

Real-time compliance dashboard provides visibility across all facilities and products.

Risk Reduction

Reduces the risk of registration lapses — and the FDA enforcement exposure that can follow — by surfacing deadlines centrally.

Regulatory Framework Applied

Establishment Registration:
21 CFR Part 207 (annual renewal required)
Product Listing:
21 CFR 207.33 (SPL submissions)
GDUFA Fees:
Self-Identified Facility: $229,070/yr (FY2026)
PDUFA Program Fee:
$417,271/yr per approved NDA/BLA (FY2026)
US Agent Requirement:
21 CFR 207.40 (foreign establishments)
Registration System:
FURLS (FDA Unified Registration and Listing System)

Understanding PDUFA and GDUFA Fees

Pharmaceutical companies face two major FDA user fee programs: PDUFA (Prescription Drug User Fee Act) applies to innovator drug companies and charges annual program fees of $417,271 per approved NDA/BLA product. GDUFA (Generic Drug User Fee Act) applies to generic drug manufacturers and charges facility fees based on whether the site produces finished dosage forms or APIs. For companies with multiple facilities, proper categorization of each site can yield significant fee savings. GDUFA fees are invoiced annually and must be paid within 30 days -- failure to pay results in facility registration suspension.

Illustrative Cost Breakdown

The figures below are illustrative estimates of the overhead a fragmented multi-facility setup can carry, not a billed result from a specific client.

CategoryBefore (Annual)After (Annual)Savings
Consultant fees (8 vendors)$480,000$180,000$300,000
Internal coordination overhead$120,000$35,000$85,000
GDUFA fee optimization--$45,000
Avoided registration lapse costs--$90,000*
TOTAL ANNUAL SAVINGS$600,000$215,000$520,000

*Estimated based on historical lapse frequency and associated costs

Implementation Timeline

Month 1

Comprehensive audit and gap analysis

Month 2

Vendor consolidation and transition

Month 3-4

Data remediation and standardization

Month 5-6

System optimization and training

When facilities each manage FDA compliance their own way, there is no central visibility and deadlines are easy to miss. Consolidating registration and listing into one workflow gives a global team real-time visibility into compliance status and removes the duplicated overhead of separate local consultants.

Managing Multi-Facility Compliance?

If you're struggling with compliance across multiple facilities, we can help you centralize, optimize, and reduce costs while improving oversight.

Get Multi-Site HelpPharmaceutical Services